Disc Medicine (IRON) EBITDA (2020 - 2026)
Disc Medicine (IRON) reported EBITDA of -$69.5 million for Q1 2026, down 74.04% year-over-year from -$267.9 million in Q1 2025, and down 3.81% on a QoQ basis from -$67.0 million in Q4 2025.
Disc Medicine (IRON) has 7 years of EBITDA data on file, last reported at -$69.5 million in Q1 2026.
- Quarterly EBITDA fell 74.04% year-over-year to -$69.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$265.6 million (down 92.18% YoY) and the FY2025 annual result came in at -$236.0 million, down 81.95% from the prior year.
- EBITDA eased to -$69.5 million in Q1 2026 per IRON's latest filing, from -$67.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$10.0 million in Q1 2022 and bottomed at -$69.5 million in Q1 2026.
- The 5-year median for EBITDA is -$30.9 million (2024), against an average of -$33.8 million.
- Peak annual rise in EBITDA reached 43.2% in 2022, while the deepest fall reached 173.9% in 2022.
- Tracing IRON's EBITDA over 5 years: stood at -$15.0 million in 2022, then slumped by 97.82% to -$29.7 million in 2023, then slipped by 16.28% to -$34.6 million in 2024, then tumbled by 93.84% to -$67.0 million in 2025, then retreated by 3.81% to -$69.5 million in 2026.
- Per Business Quant, the three latest IRON EBITDA figures stand at -$69.5 million (Q1 2026), -$67.0 million (Q4 2025), and -$67.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -69.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.52 Mn |
| Dec 31, 2025 | -66.97 Mn |
| Sep 30, 2025 | -67.70 Mn |
| Jun 30, 2025 | -61.41 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | -34.55 Mn |
| Sep 30, 2024 | -32.86 Mn |
| Jun 30, 2024 | -30.85 Mn |
| Mar 31, 2024 | -31.46 Mn |
| Dec 31, 2023 | -29.71 Mn |
| Sep 30, 2023 | -18.96 Mn |
| Jun 30, 2023 | -17.33 Mn |
| Mar 31, 2023 | -25.13 Mn |
| Dec 31, 2022 | -15.02 Mn |
| Sep 30, 2022 | -10.48 Mn |
| Jun 30, 2022 | -12.02 Mn |
| Mar 31, 2022 | -9.96 Mn |
| Dec 31, 2021 | 20.33 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -16.32 Mn |
| Mar 31, 2021 | -16.49 Mn |
| Dec 31, 2020 | -817,028.00 |
| Sep 30, 2020 | -7.95 Mn |
| Jun 30, 2020 | -6.67 Mn |
| Mar 31, 2020 | -9.63 Mn |